Doc,
While I agree with you, I also think that a company needs to be flexible enough to change their plans based on circumstances. At one time I was of the belief that the company would be bought out, now I'm convinced that investors would be better served if it remained independent, but possibly partnered with one or more BP's or others. Of course everything is subject to approvals, and ultimately label expansion, if this technology ultimately gains insurance coverage in many forms of solid cancers, the sky is the limit and no buyout price should be sufficient.
People say that management is getting older, they may want to move into retirement, that's fine, that doesn't prevent new people from being found and eventually taking their place. LP could easily cut back by going from CEO to Chairman of the BOD if she wished to remain involved, but spend less time on company matters. I've seen it happen in other companies, why not here.
Gary
Market Data 
Markets 
AI
